10-QPeriod: Q1 FY2014

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2014

Filed May 8, 2014For Securities:MRK

Summary

Merck & Co., Inc. reported sales of $10.3 billion for the first quarter of 2014, a 4% decrease compared to the prior year period, impacted by foreign exchange headwinds and the divestiture of certain product lines. Net income attributable to Merck & Co., Inc. was $1.7 billion, an increase from $1.6 billion in Q1 2013, with diluted EPS rising to $0.57 from $0.52. This improvement in profitability, despite lower sales, was driven by a significant reduction in operating expenses, particularly R&D and marketing, partly due to ongoing restructuring efforts aimed at cost savings. The company also announced a significant strategic move: the planned divestiture of its Consumer Care business to Bayer for $14.2 billion, expected to close in the second half of 2014. Proceeds will be used to fund high-growth areas, enhance the pipeline, and return capital to shareholders. In parallel, Merck entered into a collaboration with Bayer on soluble guanylate cyclase modulators, signaling a strategic focus on core pharmaceutical and vaccine businesses. Investors should monitor the integration of these strategic shifts and the impact of ongoing patent expirations and generic competition on key products.

Financial Highlights

52 data points
Beta

Revenue

$10.26B

62.0% Gross Margin

Net Income

$1.71B

16.6% Net Margin

EPS (Diluted)

$0.57

Total Assets

$108.46B

Cash & Equivalents

$15.83B

Free Cash Flow

$2.36B

Financial Statements
Beta
Revenue$10.26B
Cost of Revenue$3.90B
Gross Profit$6.36B
R&D Expenses$1.57B
SG&A Expenses$2.73B
Interest Expense$188.00M
Net Income$1.71B
EPS (Basic)$0.58
EPS (Diluted)$0.57
Shares Outstanding (Basic)2.93B
Shares Outstanding (Diluted)2.97B

Key Highlights

  • 1Sales decreased by 4% to $10.3 billion in Q1 2014 compared to Q1 2013, affected by foreign exchange and divestitures.
  • 2Net income attributable to Merck & Co., Inc. increased to $1.7 billion from $1.6 billion, and diluted EPS grew to $0.57 from $0.52.
  • 3Merck announced the divestiture of its Consumer Care business to Bayer for $14.2 billion, expected to close in H2 2014.
  • 4Research and Development expenses decreased by 17% to $1.6 billion, reflecting cost savings from restructuring and portfolio prioritization.
  • 5The company is advancing its pipeline, notably with the FDA review of MK-3475 (anti-PD-1 antibody) for melanoma, which received Priority Review designation.
  • 6Restructuring costs amounted to $125 million, with ongoing efforts expected to yield significant annual net cost savings.
  • 7The company continues to face pricing pressures and austerity measures in international markets, impacting revenue performance.

Frequently Asked Questions

The sales decline of 4% to $10.3 billion in Q1 2014 was primarily driven by lower sales of key products like Temodar, Nasonex, Singulair, and Cozaar/Hyzaar, as well as reduced revenue from the AstraZeneca LP relationship and prior divestitures. Foreign exchange also had an unfavorable impact of 2% on global sales.

Merck is executing a global restructuring program initiated in late 2013, aimed at sharpening commercial and R&D focus and improving efficiency. This involves workforce reductions and facility consolidation. The company expects annual net cost savings of approximately $2.0 billion from the 2013 program by the end of 2015, and combined with remaining actions from prior restructurings, total savings of $2.5 billion by the end of 2015 compared to 2012 levels. Significant restructuring costs were recorded in Q1 2014.

The planned sale of the Consumer Care business to Bayer for $14.2 billion represents a significant strategic divestiture, allowing Merck to focus on its core pharmaceutical and vaccine businesses. The proceeds are intended to fund growth opportunities (like MK-3475), enhance the pipeline through external assets, and return capital to shareholders. This aligns with a strategy to streamline operations and concentrate on higher-growth areas.

Merck is involved in various legal proceedings, including product liability lawsuits (Vioxx, Fosamax, Januvia, NuvaRing, Propecia) and patent litigation. The company actively defends its legal positions and has established reserves for known liabilities, such as settlements for Vioxx and Fosamax. Management believes its reserves are adequate, but acknowledges that unfavorable outcomes in significant litigation could materially affect financial position and results of operations.